1. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. (October 2020) Authors: Fu, Weihui; Liu, Yan; Liu, Li; Hu, Huiliang; Cheng, Xiaobo; Liu, Ping; Song, Zhigang; Zha, Lijun; Bai, Shimeng; Xu, Tingting; Yuan, Songhua; Lu, Fengru; Shang, Zhiying; Zhao, Yihong; Wang, Jing; Zhao, Jun; Ding, Longfei; Chen, Jun; Zhang, Lin; Zhu, Tongyu Journal: EClinicalMedicine Issue: Volume 27(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗